On the September 8 episode of Mad Money, Jim Cramer described medical device company Medtronic (MDT) as a "quandary," noting its strong organic growth and the planned separation of its diabetes division by year-end. Medtronic reported fiscal first-quarter 2027 revenue of nearly $9.8 billion, up 13.7% organically, with non-GAAP diluted EPS rising 15.1% to $1.45. The company raised its full-year organic revenue-growth forecast to 7.25%-7.75% and increased the lower end of its non-GAAP diluted EPS guidance to $5.94. Cramer highlighted the stock's current position despite significant year-over-year business improvement.